Genmab — September 2024
-
Godmorgen.
-
DARZALEX
(daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned https://www.globenewswire.com/en/news-release/2024/09/27/2954641/0/en/DARZALEX-daratumumab-subcutaneous-SC-formulation-based-quadruplet-regimen-significantly-improves-minimal-residual-disease-negativity-for-newly-diagnosed-multiple-myeloma-patients-f.html -
IMS 2024 – Darzalex fights back against Sarclisa https://www.oncologypipeline.com/apexonco/ims-2024-darzalex-fights-back-against-sarclisa
-
Carvykti med gode 3 års data i second line https://finance.yahoo.com/news/carvykti-first-only-cell-therapy-203000097.html
-
After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data https://www.fiercepharma.com/pharma/after-sanofis-first-line-myeloma-nod-jj-strikes-back-new-tranche-darzalex-data
-
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art
Therapeutic Advances in Medical Oncology https://journals.sagepub.com/doi/10.1177/17588359241277647
-
-
-
the company can breathe a bit easier thanks to the assumption that Darzalex Faspro, the Halozyme-partnered subcutaneous version of J&J’s multiple myeloma blockbuster, will be safe from price negotiations for the foreseeable future thanks to its under-the-skin formulation, Taubert said
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind